https://en.wikipedia.org/wiki/Interferon_alfa-2b
*Interferon alfa-2b* is an antiviral or antineoplastic <https://en.wikipedia.org/wiki/Antineoplastic> drug, that was originally discovered in the laboratory of Charles Weissmann <https://en.wikipedia.org/wiki/Charles_Weissmann> at the University of Zurich[*citation needed <https://en.wikipedia.org/wiki/Wikipedia:Citation_needed>*]. It was developed at Biogen, and ultimately marketed by Schering-Plough under the tradename *Intron-A*. It has been used for a wide range of indications, including viral infections and cancers. This drug is approved around the world for the treatment of chronic hepatitis C <https://en.wikipedia.org/wiki/Hepatitis_C>, chronic hepatitis B <https://en.wikipedia.org/wiki/Hepatitis_B>, hairy cell leukemia, Behçet's disease <https://en.wikipedia.org/wiki/Beh%C3%A7et%27s_disease>, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, mastocytosis and malignant melanoma. The medication has also been used to treat patients with Severe acute respiratory syndrome coronavirus 2 <https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome_coronavirus_2> ..[1] <https://en.wikipedia.org/wiki/Interferon_alfa-2b#cite_note-1>[2] <https://en.wikipedia.org/wiki/Interferon_alfa-2b#cite_note-2>
